Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from NLS Pharmaceutics ( (NLSP) ) is now available.
On January 31, 2025, shareholders of Kadimastem approved a merger with NLS Pharmaceutics, marking a significant step toward forming a combined Nasdaq-traded biotechnology entity. This merger is expected to enhance their portfolio with advanced therapies for neurodegenerative diseases and diabetes, highlighting the companies’ commitment to addressing unmet medical needs in the biopharmaceutical sector.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company that focuses on discovering and developing innovative therapies for rare and complex central nervous system disorders. Kadimastem Ltd. is a clinical-stage cell therapy company based in Israel, specializing in ‘off-the-shelf’ allogeneic cell products for neurodegenerative diseases and diabetes.
YTD Price Performance: -9.17%
Average Trading Volume: 1,202,706
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.9M
For an in-depth examination of NLSP stock, go to TipRanks’ Stock Analysis page.
